Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1Melanoma 1Lethal Congenital Contracture Syndrome 2 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 41Specimen Handling 39Magnetic Resonance Spectroscopy 30Carboplatin 29Biopsy 25Cyclophosphamide 23Nivolumab 22Dexamethasone 20Gemcitabine 18fludarabine 17Bevacizumab 15atezolizumab 14Pemetrexed 13Paclitaxel 13Ipilimumab 13Docetaxel 13Cisplatin 13Temozolomide 12venetoclax 11Rituximab 11Prednisone 10X-Rays 9Injections 9Vincristine 8Oxaliplatin 8Lenalidomide 8Fluorouracil 8Cytarabine 8Capecitabine 8tocilizumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Paroxetine × 30 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡